Low dose anti-thymocyte globulin reduces chronic graft-versus-host disease incidence rates after matched unrelated donor transplantation-Reference-Cited by-同舟云学术

Low dose anti-thymocyte globulin reduces chronic graft-versus-host disease incidence rates after matched unrelated donor transplantation

Published:2017-12-04 Issue:7 Volume:59 Page:1644-1651
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Tandra Anand¹,Covut Fahrettin¹,Cooper Brenda¹,Creger Richard¹,Brister Lauren¹,McQuigg Bernadette¹,Caimi Paolo¹,Malek Ehsan¹,Tomlinson Ben¹,Lazarus Hillard M.¹,Otegbeye Folashade¹,Kolk Merle¹,de Lima Marcos¹,Metheny Leland¹

Affiliation:

1. Stem Cell Transplant Program, University Hospitals Cleveland Medical Center and Case Western Reserve University, Cleveland, OH, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2017.1390234

Reference37 articles.

1. Immunobiology of Allogeneic Hematopoietic Stem Cell Transplantation

2. Back to the Future: Mismatched Unrelated Donor, Haploidentical Related Donor, or Unrelated Umbilical Cord Blood Transplantation?

3. Prospective Evaluation of Allogeneic Hematopoietic Stem-Cell Transplantation From Matched Related and Matched Unrelated Donors in Younger Adults With High-Risk Acute Myeloid Leukemia: German-Austrian Trial AMLHD98A

4. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial

5. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO)

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention;Blood Advances;2024-08-15

2. Allogeneic stem cell transplant recipients surviving at least 2 years without relapse: outcome and risk factors;eJHaem;2024-02

3. Effect of antithymocyte globulin on chronic GVHD and prognosis of allogeneic hematopoietic stem cell transplantation;Japanese Journal of Transplantation and Cellular Therapy;2022

4. Graft-Versus-Host Disease Prophylaxis Using Low-Dose Antithymocyte Globulin in Peripheral Blood Stem Cell Transplantation—A Matched-Pair Analysis;Transplantation and Cellular Therapy;2021-12

5. Low-dose antithymocyte globulin inhibits chronic graft-versus-host disease in peripheral blood stem cell transplantation from unrelated donors;Bone Marrow Transplantation;2021-05-07